Press Releases Natera, Inc.

Stocks

NTRA

US6323071042

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 21:00:00 12/06/2026 BST			5-day change	1st Jan Change
212.07 ^USD	-3.27%		-1.50%	-7.43%

06-13	Natera, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 09:20 AM
06-12	Natera MRD Leadership Supported by 'Durable' High-Value Market, RBC Says	MT

Press Releases

06-09	Natera : Initial Statement of Beneficial Ownership (Form 3)	PU
06-04	Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer	BU
06-03	Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors	BU
05-29	Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma	BU
05-28	Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer	BU
05-27	Natera to Launch Enhanced Panorama NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology	AQ
05-26	Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology	BU
05-21	Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology	BU
05-21	Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World	BU
05-20	EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled	BU
05-15	Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)	BU
05-07	Natera: Q1 Earnings Snapshot	AQ
05-07	Natera : Q1 2026 Earnings Presentation	PU
05-07	Natera Reports First Quarter 2026 Financial Results	BU
04-30	Natera to Report its First Quarter Results on May 7, 2026	BU
04-22	Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT	BU
04-13	Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma	BU
04-09	Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents	BU
04-07	20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform	BU
03-31	SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery	BU
03-16	Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers	BU
03-13	Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis	AQ
03-12	Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis	BU
03-12	MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026	PR
03-04	Delhi High Court Dismisses Appeal Against Refusal Of Smelling Disease Patent	AQ